NIH: Francis Collins
Francis Collins is stepping down as director of the National Institutes of Health at the end of this year. He is the longest-serving presidentially appointed NIH director, serving in this role since August 2009. Before that, he was the director of the National Human Genome Research Institute from 1993 to 2008, where he led the international Human Genome Project. During his tenure as NIH director, he launched the All of Us Research Program, worked with then-Vice President Joe Biden to launch the Cancer Moonshot Initiative, and was involved in establishing numerous other programs and initiatives. Collins will continue to lead his research laboratory at NHGRI, which focuses on type 2 diabetes and new genetic therapies for Hutchinson-Gilford progeria syndrome.
To read more about Collins' departure, click here.
Oncocyte: Gisela Paulsen
Oncocyte has appointed Gisela Paulsen as its chief operating officer. She joins the company having most recently served as general manager of Genomic Health following its acquisition by Exact Sciences. She has also held senior roles at Roche/Genentech and Health Learning Systems, the founding medical education unit of Ogilvy. Paulsen is currently an entrepreneur in residence at DigitalDX Ventures and has served on the board of directors of the healthcare businesswomen association, CuriOdyssey, and the Genentech Foundation.
Roswell Biotechnologies: Mike Aicher
Roswell Biotechnologies, a company developing single-molecular analysis platforms based on semiconductor chip technology, has appointed Mike Aicher as chairman of its board of directors. Aicher was president and founder of Alveo Technologies, an infectious disease testing startup. He cofounded and served as CEO of the National Genetics Institute (which became part of LabCorp in 2000) for more than two decades. He is also an executive director at Genetic Signatures, chairman of CytoBay, and a member of Techcyte's board of directors. Aicher previously served on the board of directors for Fabric Genomics, and was a board member of Ariosa until its acquisition by Roche.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.